
RSH-7
CAS No. 2764609-97-2
RSH-7( —— )
Catalog No. M36539 CAS No. 2764609-97-2
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 147 | In Stock |
![]() ![]() |
5MG | 250 | In Stock |
![]() ![]() |
10MG | 407 | In Stock |
![]() ![]() |
25MG | 748 | In Stock |
![]() ![]() |
50MG | 1086 | In Stock |
![]() ![]() |
100MG | 1458 | In Stock |
![]() ![]() |
500MG | 2907 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRSH-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionRSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
-
DescriptionRSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively. RSH-7 induces apoptosis and shows antiproliferative activities. RSH-7 inhibits BTK and FLT3 signaling and shows anti-tumor activity.
-
In VitroRSH-7 (1-1000 nM; 72 h) shows antiproliferative activities with IC50s of 17, 3, 11, 930 nM for Jeko-1, MV-4-11, Molt4, K562 cells, respectively.RSH-7 (30, 150, 750 nM; 72 h) decreases the expression of p-BTK (TYR223), p-PLCγ(Tyr1217), p-FLT3 (Tyr589), p-STAT5 (TYR694) in a dose-dependent manner.RSH-7 (30, 150, 750 nM; 72 h) induces apoptosis and increases the expression of BAX, p53, cleaved caspase 3 in a dose dependen manner in jeko-1 cells..Cell Viability Assay Cell Line:Jeko-1, MV-4-11, Molt4, K562 cells Concentration:1-1000 nM Incubation Time:72 h Result:Showed antiproliferative activities with IC50s of 17, 3, 11, 930 nM for Jeko-1, MV-4-11, Molt4, K562 cells, respectively.Western Blot Analysis Cell Line:jeko-1 cells Concentration:30, 150, 750 nM Incubation Time:72 h Result:Reduced both BTK, PLCγ2, FLT3 and STAT5 phosphorylation in a dose-dependent manner.Apoptosis Analysis Cell Line:jeko-1 cellsConcentration:30, 150, 750 nM Incubation Time:72 h Result:Dose-dependently induced cell apoptosis and upregulated the expression of pro-apoptotic protein BAX, p53, cleaved caspase 3.
-
In VivoRSH-7 (25, 50 mg/kg; i.p.; daily for 16 days) shows anti-tumor activity with significantly and dose-dependently suppresses the tumor growth in mouse.Animal Model:Female NOD/SCID mice (jeko-1 cell-inoculated xenograft NOD/SCID mice models)Dosage:25, 50 mg/kg Administration:I.p.; daily for 16 days Result:Suppressed tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) values of 66.95% and 79.78% at doses of 25 and 50 mg/kg,Animal Model:Female NOD/SCID mice (MV4-11 cell-inoculated xenograft NOD/SCID mice models)Dosage:10, 20 mg/kg Administration:I.p.; daily for 21 days Result:Significantly and dose-dependently suppressed the tumor growth with the TGI rates of 74.23% and 94.84% at the dosage of 10 and 20 mg/kg, respectively.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | FLT | BTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2764609-97-2
-
Formula Weight436.49
-
Molecular FormulaC22H25FN8O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (190.91 mM; Ultrasonic )
-
SMILESN(C1=C(C(NN)=O)C=CC=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=NC=C2F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ran F, et al. Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114913.?
molnova catalog



related products
-
L-Cystathionine
L-Cystathionine is a key nonprotein amino acid related to metabolic conditions of sulfur-containing amino acids.
-
ABT-510 acetate
ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
-
AAPK-25
AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.